![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
. | ![]() |
. |
![]() by Staff Writers Geneva (AFP) Dec 1, 2020
A strawberry-flavoured HIV treatment for the 1.7 million children living with the virus will slash the cost of yearly paediatric drugs by three quarters, Unitaid announced on World AIDS Day. The dispersible HIV treatment is the first specifically made for children and will initially be available in six African countries in the first half of 2021, the global health development organisation said in a statement. The new formulation of the recommended first-line HIV treatment dolutegravir (DTG) will be made as a 10-milligramme strawberry-flavoured, dispersible tablet. "A long-awaited HIV treatment designed specifically for children will now be available in low- and middle-income countries," Unitaid said Tuesday. "The new pricing agreement with generic manufacturers Viatris and Macleods means a new dispersible formulation of... DTG will be launched at a yearly cost of $36 per child, reduced from around $400." This will bring down the total cost of yearly paediatric HIV treatment by three quarters, from over $480 per child to under $120, said Unitaid, which works in partnership with the World Health Organization (WHO). - 100,000 child deaths annually - Of the 1.7 million children living with HIV, around 100,000 die every year, said Unitaid. It said that many children living with HIV have a poor response to treatment because they take anti-retroviral medication that is not correctly dosed, bitter to taste, or in tablet format that is difficult for babies to swallow. An affordable DTG has thus far been unavailable for children weighing under 20 kilogrammes due to a lack of dispersible tablets, which are considered age-appropriate formulations, Unitaid said. The product will be made initially available in Benin, Kenya, Malawi, Nigeria, Uganda and Zimbabwe in the first half of 2021, with other countries set to follow. Meg Doherty, the WHO's global HIV programme director, said there were 26 million people on anti-retroviral therapy worldwide. She told journalists that out of 127 countries surveyed by the UN health agency, 12 were reporting critically-low stocks of anti-retroviral medicines due to the Covid-19 pandemic. Many countries are getting around restrictions relating to the coronavirus crisis by distributing several months' worth of drugs at a time to patients.
![]() ![]() Pakistanis join final trials for China-made vaccine Islamabad (AFP) Nov 26, 2020 Thousands of volunteers are flocking to research hospitals across Pakistan to join final-stage clinical trials of a Chinese-made vaccine for the coronavirus. It is the first time Pakistan has participated in such a trial, which comes amid a string of positive vaccine announcements by Western pharmaceutical companies this month. The vaccine is being developed by CanSinoBio and the Beijing Institute of Biotechnology China. "I have volunteered myself for a noble cause that will help humanity," ... read more
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |